# EDGAR Filing Document

**Accession Number:** 0001636651
**File Stem:** 0001193125-25-327040
**Filing Date:** 2025-12
**Character Count:** 2542
**Document Hash:** 48575be103a2b22a128448c4d6a82133
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-327040.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001193125-25-327040

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ovid Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001636651
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465270895
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 441 NINTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 212-776-4381

**MAIL ADDRESS:**
- **STREET 1:** 441 NINTH AVENUE, 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**Ovid Therapeutics Inc.** 

**441 Ninth Avenue, 14<sup>th</sup> Floor** 

**New York, New York 10001** 

December 19, 2025

**<u>VIA EDGAR</u>**

Division of Corporation Finance

Office of Technology

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **RE:** | **Ovid Therapeutics Inc.**  |

---

**Registration Statement on Form S-3** 

**File No. 333-292151** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, Ovid Therapeutics Inc. (the "**Registrant**") hereby requests that the U.S. Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on December 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Laura Berezin and Jaime L. Chase of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Jaime L. Chase at (202) 728-7096, or in her absence, Laura Berezin of Cooley LLP, counsel to the Registrant, at (650) 843-5128.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **OVID THERAPEUTICS INC.** | **OVID THERAPEUTICS INC.** |
| By: | /s/ Jeff Rona |
| Name: | Jeff Rona |
| Title: | Chief Business and Chief Financial Officer |

---

cc: Jeff Rona, Ovid Therapeutics Inc.

Laura Berezin, Cooley LLP

Jaime L. Chase, Cooley LLP